Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations
about
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsIntrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCManagement of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistanceThe Evolution of Therapies in Non-Small Cell Lung CancerA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesCombating acquired resistance to tyrosine kinase inhibitors in lung cancerEGFR mutations as a prognostic and predictive marker in non-small-cell lung cancerUpdate in Lung Cancer 2014Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung AdenocarcinomaUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsPersonalized treatment of advanced non-small-cell lung cancer in routine clinical practiceNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceSrc inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFRThird-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerTriplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond ProgressionRedundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2AEGFR: The Paradigm of an Oncogene-Driven Lung CancerEpidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone.Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on AfatinibIncreased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted TherapiesAdvances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung AdenocarcinomaDigital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.Opportunities and challenges in combination gene cancer therapy.A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow.Targeting EGFR in lung cancer: Lessons learned and future perspectives
P2860
Q26741318-3CC28105-22B4-4A70-AA9F-10F18D1932CCQ26744339-19AC6A67-ED97-413C-B38D-4A1D361CAD9AQ26745427-84668E91-6CBC-40D5-9CE2-A2C7A02174E3Q26747276-EF380FB2-C7DA-4CDD-8EAC-04BE78F272B4Q26775379-CDF0A810-CD5F-41E1-89B7-D839EFDD317CQ26786932-42131C1A-0661-4C15-9805-515D8016F287Q26797297-3525E60F-6D74-4004-A38E-51176E7B3C98Q26824877-F001D2C3-AA0F-437E-BF5E-9BD0121EA2A7Q26852507-27EF2801-0BDC-4885-B150-3E6E993D9301Q27027385-F9344BC4-89F0-4A93-91DB-B7FDEABCA55DQ28069900-D26AA465-1382-4FB3-A897-9B6A3CD40493Q28075291-B94396EB-3CF8-44B2-B62A-52B59EA3925BQ28075800-A4FE00F6-080A-4872-BCE1-350F7F35BA06Q28079320-52611A79-87F9-49F9-AE95-98FCA847E60EQ30278774-80D1A01F-6934-4108-A2DE-A4E0AE18AB2CQ33618558-AB1EC6B0-CA76-4B0D-80BA-E891303B41E0Q33740707-9ADE340F-7C58-40BE-BD0C-84777AD14358Q33787355-B2A4371B-AF23-459D-8EF7-784923CE581EQ34260686-09C18E41-D4EE-4793-A5E3-4FD9159C2D78Q34497467-D379FD22-B655-41CC-8172-1155CC6A14C6Q34650994-DE645792-D3A3-49C9-B32D-4FF9D8D46AFCQ34704781-9969CDC8-0388-4EAD-B066-5C6D24A78F02Q35112467-CE1FFB90-7D0D-44D4-860A-C9BB2956FDBBQ35273471-AF0AE8CD-214B-4A2D-9644-F72B74099545Q35619241-CB993FB9-E192-4BF9-A63E-640B04AB782BQ35793804-46BD76A3-324F-45AE-B3AF-EFBBA559E90CQ35807946-1B9EB5A2-0415-4F53-994C-690D0642846FQ36172627-2A742B09-4C4B-4626-A382-DE6DB393DC40Q36358523-F9BC3D8E-DE75-4A4D-8B47-AD1038459640Q36471537-E2F9F006-BD5A-4E4C-939C-8977550E8DE7Q36544438-CB5921BD-766A-46CA-A0BB-AEE84A317D9CQ36544650-ABEE7DA3-5ED4-4E87-8F06-38B905A19D05Q36627196-852D0C2E-F3D0-4EDD-B7BE-A75522AB0C4DQ36687288-B3133B65-069E-4E54-9FAE-751A86803FCBQ36797398-0D110059-4077-4E8E-8943-3CC200BFA806Q36938818-B2B5E5C8-7D88-48C0-BA26-54F10F0CFD49Q37085219-C0683394-8250-4903-9501-C0D07A819C10Q37118663-2685ACAC-43C6-4640-9ED7-91537281A526Q37187713-D32598E8-C9B3-491A-8F2E-463D5698E14DQ37258827-0DF59471-A38A-4367-A58E-C0613522FD70
P2860
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Dual inhibition of EGFR with a ...... th and without T790M mutations
@ast
Dual inhibition of EGFR with a ...... th and without T790M mutations
@en
Dual inhibition of EGFR with a ...... th and without T790M mutations
@nl
type
label
Dual inhibition of EGFR with a ...... th and without T790M mutations
@ast
Dual inhibition of EGFR with a ...... th and without T790M mutations
@en
Dual inhibition of EGFR with a ...... th and without T790M mutations
@nl
prefLabel
Dual inhibition of EGFR with a ...... th and without T790M mutations
@ast
Dual inhibition of EGFR with a ...... th and without T790M mutations
@en
Dual inhibition of EGFR with a ...... th and without T790M mutations
@nl
P2093
P2860
P1433
P1476
Dual inhibition of EGFR with a ...... th and without T790M mutations
@en
P2093
Bushi Wang
D Ross Camidge
Egbert F Smit
Gregory J Riely
Harry J M Groen
Leora Horn
Vikram K Chand
Vincent A Miller
Yelena Y Janjigian
P2860
P304
P356
10.1158/2159-8290.CD-14-0326
P577
2014-07-29T00:00:00Z